Zobrazeno 1 - 10
of 12
pro vyhledávání: '"V. M. Tsvetov"'
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 11-14 (2020)
Until clinical trials of efficacy and safety are obtained, routine use of barycytinib in patients with COVID-19 cannot be recommended.
Externí odkaz:
https://doaj.org/article/c60142645dd043a088ed3240cf23ff6f
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 39-46 (2020)
Impaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug
Externí odkaz:
https://doaj.org/article/eefaef53ceca4ec982953d6774cca397
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 99-102 (2020)
There are prerequisites for the use of remdesivir against SARS-CoV-2 in stationary conditions. Remdesivir is not registered in the Russian Federation. The preliminary results of randomized clinical trials on the efficacy of remission are contradictor
Externí odkaz:
https://doaj.org/article/06d132b6e75b4845b38c0ac112f3dad9
Autor:
Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, K. B. Mirzaev, V. A. Otdelenov, V. M. Tsvetov, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 75-80 (2020)
At the time of print, the evidence for using umifenovir in COVID-19 is mainly theoretical. The published clinical trials have contradicting results. The decision to use umifenovir in COVID-19 should be individualized, considering the “experimental
Externí odkaz:
https://doaj.org/article/086bc563d1bf4e7db1fc4d0bf2b37ae3
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 92-95 (2020)
Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature o
Externí odkaz:
https://doaj.org/article/1efabadbcbe24a0ea5a28f075d2bb7ec
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 4-7 (2020)
There are no data on the clinical efficacy of the preparation containing sodium aminodihydrophthalazindione in «cytokine storm», including in patients with COVID-19. Protocols of planned or ongoing clinical trials of a preparation containing sodium
Externí odkaz:
https://doaj.org/article/56938ffe77824b8e8c06d36e9d965710
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 15-17 (2020)
Routine clinical use of riamilovir in COVID-19 is not recommended. The use of riamilovir is possible in clinical trials.
Externí odkaz:
https://doaj.org/article/fa1bb870c77b4e51b9fda925deb2c422
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 68-70 (2020)
Routine clinical use of olokizumab in COVID-19 is not recommended. The use of olokizumab is possible in clinical trials.
Externí odkaz:
https://doaj.org/article/1b429c37cc9a4d7cbc00aad081552c14
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4S, Pp 47-49 (2020)
Some guidelines describe combined use of hydroxychloroquine and lopinavir/ritonavir as one of the treatment alternatives for severe COVID-19, yet this treatment is not preferable. It requires careful consideration of possible interactions with other
Externí odkaz:
https://doaj.org/article/89914ec010bb4e33b3be38adc7e46feb
Autor:
D. V. Ivashchenko, K. A. Zagorodnikova, V. M. Tsvetov, V. V. Poroikov, A. V. Dmitriev, D. A. Sychev, A. V. Krykov, A. S. Matveev, Vitaly Otdelenov, Yu.Yu. Kiselev Kiselev, Igor N. Sychev, K. B. Mirzaev
Publikováno v:
Kachestvennaya klinicheskaya praktika. :75-80
At the time of print, the evidence for using umifenovir in COVID-19 is mainly theoretical. The published clinical trials have contradicting results. The decision to use umifenovir in COVID-19 should be individualized, considering the “experimental
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa85284a7685bb32150bfe4ee33fca70
https://doi.org/10.37489/2588-0519-2020-s4-75-80
https://doi.org/10.37489/2588-0519-2020-s4-75-80